Efficacy and tolerability of horse chestnut seed extract on swelling in patients undergoing meniscus surgery: a placebo-controlled, randomized, double-blind, single-center, pilot study - CES AES 01/21

Start Date24 Nov 2023

Sponsor / Collaborator

Cesra Arzneimittel GmbH & Co. KG

DRKS00031074 / CompletedPhase 2

Efficacy and tolerability of horse chestnut seed extract to improve microcirculation in diabetic patients: a placebo-controlled, randomised, double-blind, crossover, single-centre, pilot study - CES_AES_02/21

Start Date22 Feb 2023

Sponsor / Collaborator

Cesra Arzneimittel GmbH & Co. KG

EUCTR2016-005105-39-DE / Not yet recruitingPhase 4

Investigation of the effectiveness, tolerability and safety of ilon® Salbe classic in the treatment of acute inflammation of the hair follicle (folliculitis) - Prospective, open, evaluator-blinded, randomized, placebo-controlled multicenter trialInvestigation of the effectiveness, tolerability and safety of ilon® Salbe classic in the treatment of acute inflammation of the hair follicle (folliculitis) - Prospective, open, randomized, placebo-/comparator controlled multicenter trial (previous title – feasibility study)

Start Date12 Jun 2017

Sponsor / Collaborator

Cesra Arzneimittel GmbH & Co. KG

100 Clinical Results associated with Cesra Arzneimittel GmbH & Co. KG

0 Patents (Medical) associated with Cesra Arzneimittel GmbH & Co. KG

Literatures (Medical) associated with Cesra Arzneimittel GmbH & Co. KG

01 Oct 2024·Planta Medica

In Vitro Anti-inflammatory Effects of Larch Turpentine, Turpentine Oil, Eucalyptus Oil, and Their Mixture as Contained in a Marketed Ointment

Article

Author: Günnewich, Nils ; Zimmermann, Christian ; Appel, Kurt ; Rose, Thorsten

AbstractAn ointment containing larch turpentine, turpentine oil, and eucalyptus oil has been used for almost a century for the symptomatic treatment of mild, localized, purulent inflammations of the skin. Its clinical efficacy in the treatment of skin infections has been shown in clinical trials, but the mode of action of the active ingredients on inflammation is not known. We studied the anti-inflammatory properties of the active ingredients of the ointment and their mixture in a human monocyte cell model, in which the cells were stimulated with lipopolysaccharide and incubated with the test substances. The cytotoxic threshold of each test substance and the mixture was identified using the alamarBlue assay, and their anti-inflammatory activity was assessed by measuring the release of interleukins IL-1β, IL-6, IL-8, monocyte chemoattractant protein-1, prostaglandin E2, and TNF-α. Cell toxicity was observed at a mixture concentration of 10 µg/mL. All immunological assays were carried out at nontoxic concentrations. Larch turpentine decreased IL-1β, monocyte chemoattractant protein-1, and prostaglandin E2 release at a concentration of 3.9 µg/mL and TNF-α at concentrations > 1.95 µg/mL, whereas eucalyptus oil and turpentine oil had no relevant inhibitory effects. The mixture dose-dependently inhibited IL-1β, IL-6, monocyte chemoattractant protein-1, prostaglandin E2, and TNF-α release at concentrations > 1 µg/mL. IL-8 release was only marginally affected. The anti-inflammatory activity of the herbal ingredients and their mixture was confirmed in this model. This effect seems to be mediated mainly by larch turpentine, with turpentine oil and eucalyptus oil exerting an additive or possibly synergistic function.

01 Jan 2023·Complementary Medicine Research

Turpentine Ointment in Bacterial Skin Infections: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Article

Author: Günnewich, Nils ; Lorenz, Horst ; Zimmermann, Christian ; Schwarzensteiner, Ilona ; Tronnier, Hagen ; Fuchs-Algrim, Joachim ; Kaiser, Peter-Michael

Background: Turpentine-containing substances are considered effective in treating cutaneous bacterial infections, but reliable clinical data are scant. Objective: We investigated the efficacy and safety of an ointment containing larch turpentine (from Larix decidua), eucalyptus oil (from Eucalyptus globulus), and turpentine oil (from Pinus pinaster) in outpatients with painful skin abscesses in a randomized, placebo-controlled, double-blind study. Intervention: 116 outpatients with skin abscesses used verum or placebo for 10 days. Sum score of the patient’s discomforts, changes in abscess size, rate of therapeutic success, and complete healing served as outcome parameters. Results: Fifty-four patients were treated with verum and 56 with placebo. According to the patient’s discomfort sum score, patients in the verum group showed a better improvement compared to the placebo group (7.3 vs. 4.7; p = 0.024), and subjective assessment by the investigators revealed a higher treatment success rate after verum (70% vs. 48%; p = 0.021). Complete healing was documented in 67% of the patients receiving verum versus 46% in the placebo group (p = 0.037). There was a positive trend toward a larger decrease in the abscess sizes in the verum group compared to the placebo group (p = 0.07). Conclusion: The ointment studied is an effective and safe option for the treatment of bacterial skin diseases.

01 Jan 2023·Skin Pharmacology and Physiology

Turpentine Ointment for the Treatment of Folliculitis: An Open, Prospective, Randomized, Placebo- and Comparator-Controlled Multicenter Trial

Article

Author: Zimmermann, Christian ; Huber, Hilde ; Görne, Rainer C ; Günnewich, Nils ; Wallmen, Britta

Introduction: Folliculitis is a painful infection and inflammation of the hair follicles, mostly caused by bacterial, fungal, or, more rarely, viral infections. Turpentine derivatives have been used traditionally to treat various skin infections and could thus also be effective in treating folliculitis. We carried out an open, prospective, randomized, placebo- and comparator-controlled multicenter trial to evaluate the efficacy and safety of an ointment containing pine turpentine oil, larch turpentine, and eucalyptus oil in the treatment of acute folliculitis. Methods: Seventy outpatients with acute folliculitis were treated with the turpentine ointment, a comparator (povidone iodine solution), or a placebo (Vaseline) for 7 days. Photographs of the affected skin areas were taken by the physicians at four visits and by the patients on a daily basis. Photographs were evaluated by blinded observers. Primary efficacy endpoint was the change in total hair follicle lesion counts. Secondary endpoints included the evolution of the lesion counts in the course of the study, responder rate (improvement of follicle lesions by at least one count), and the patient’s global assessment. Safety endpoints were the tolerability of the treatments and adverse event recording. Results: A decrease of follicle lesions counts was detected for both active treatments but not for placebo, but the differences among groups were not statistically significant. As for the secondary endpoints, the ointment showed statistically significant superiority over placebo for the evolution of the lesions during the course of the study (p = 0.017), the responder rate (p = 0.032), and the subjective efficacy assessment by patients (p = 0.029). All treatments were equally well tolerated, with a similar number of treatment-emergent adverse events. Conclusion: The turpentine ointment is an effective and safe option for the treatment of folliculitis.

100 Deals associated with Cesra Arzneimittel GmbH & Co. KG

100 Translational Medicine associated with Cesra Arzneimittel GmbH & Co. KG

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

Current Projects

Drug(Targets)	Indications	Global Highest Phase

MaiZhiLing	Venous Thromboembolism More	Approved

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis